Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Ettinger, David S.; Wood, Douglas E.; Aisner, Dara L.; Akerley, Wallace; Bauman, Jessica R.; Chirieac, Lucian R.; D’Amico, Thomas A.; DeCamp, Malcolm M.; Dilling, Thomas J.; Dobelbower, M.C.; Doebele, Robert C.; Govindan, Ramaswamy; Gubens, Matthew A.; Hennon, Mark; Horn, Leora; Komaki, Ritsuko; Lackner, Rudy P.; Lanuti, Michael; Leal, Ticiana; Leisch, Leah J.; Lilenbaum, Rogerio; Lin, Jules; Loo, Billy W.; Martins, Renato; Otterson, Gregory A.; Reckamp, Karen L.; Riely, Gregory J.; Schild, Steven E.; Shapiro, Theresa A.; Stevenson, James; Swanson, Steven; Tauer, Kurt W.; Yang, Stephen C.; Gregory, Kristina M.; Hughes, Miranda

doi:10.6004/jnccn.2017.0050

articleJournal of the National Comprehensive Cancer NetworkApr 1, 2017Closed access

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

DSDavid S. Ettinger DEDouglas E. Wood DLDara L. Aisner WAWallace Akerley JRJessica R. Bauman

Smilow Cancer Hospital · Barnes-Jewish Hospital · +5 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

Citation impact

1,325

total citations

FWCI: 146.06
Percentile: 100%
References: 161

Citations per year

Authors

35

Topics & keywords

Topics

Keywords

Medicine
Atezolizumab
Osimertinib
Ceritinib
Pembrolizumab
Oncology
Lung cancer
Internal medicine

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.